Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the gatekeeper residue. Irreversible EGFR inhibitors, including PF00299804, are effective in vitro and in vivo against EGFR mutant tumors that contain EGFR T790M and are currently under clinical development. In this study, we generate models of resistance to PF00299804, using cell lines with EGFR T790M and show that the PF00299804-resistant models develop focal amplification of EGFR that preferentially involves the T790M-containing allele. These PF00299804-resistant cell lines remain dependent on EGFR for growth as downregulation of EGFR by shRNA compromises their viability. We show that resistance to PF00299804 arises, at least in part, through selection of a pre-existing EGFR T790M-amplified clone both in vitro and using a xenograft model in vivo. Our findings show that EGFR T790M is a common resistance mechanism to both reversible, and when amplified, the irreversible EGFR kinase inhibitors further emphasizing the need to develop more potent therapies against EGFR T790M. These findings can be used to guide studies of patient tumor specimens from ongoing clinical trials of irreversible EGFR kinase inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R et al. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110–124.
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494–6501.
Besse B, Eaton Kd, Soira JC, Lynch TJ, Miller V, Wong KK et al. (2008). Neratinib (HKI272) an irreversible pan-ErbB receptor tyrosine kinase inhibtor: preliminary results of a phase 2 tiral in patients with advanced non-small cell lung cancer. Euro J Cancer 6: 64; abstract 203..
Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. (2006). Comparison of imatinib mesylate, dasatinib (BMS-354825) and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332–2338.
Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK et al. (2005). Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011–11016.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–1338.
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042.
Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788–3793.
Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM et al. (2006). Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 116: 2695–2706.
Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T et al. (2007a). PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924–11932.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007b). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.
Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ . (2007). MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500–502.
Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese 2nd DJ et al. (2007). Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 67: 7319–7326.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880.
Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG et al. (2007). Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13: 4874–4881.
Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N et al. (2006). Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24: 3340–3346.
Janne PA, Schellens JH, Engelman JA, Eckhardt SG, Milham R, Denis LJ et al. (2008). Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 26(Suppl): abstract 8027.
Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346: 645–652.
Kaufman RJ, Schimke RT . (1981). Amplification and loss of dihydrofolate reductase genes in a Chinese hamster ovary cell line. Mol Cell Biol 1: 1069–1076.
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792.
Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M et al. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764–5769.
Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. (2008). BIBW2992 an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702–4711.
Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al. (2008). Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366–377.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957.
Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N et al. (2005). Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97: 1185–1194.
Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H et al. (2004). Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3: 465–472.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500.
Quintas-Cardama A, Cortes J . (2008). Therapeutic options against BCR-ABL1T315I positive chronic myelogenous leukemia. Clin Cancer Res 14: 4392–4399.
Rothenberg SM, Engelman JA, Le S, Riese 2nd DJ, Haber DA, Settleman J . (2008). Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci USA 105: 12480–12484.
Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL et al. (2008). Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68: 589–596.
Schellens JH, Britten CD, camidge DR, D Boss, Wong S, Diab S et al. (2007). First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible pan-HER inhibitor in patients with advanced cancer. J Clin Oncol, 2007 ASCO Annu Meet Proc Part I 25(Suppl): 3599.
Schimke RT, Kaufman RJ, Alt FW, Kellems RF . (1978). Gene amplification and drug resistance in cultured murine cells. Science 202: 1051–1055.
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA et al. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442–2449.
Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. (2008). Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14: 485–493.
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117–125.
Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL et al. (2008). Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68: 5827–5838.
Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A et al. (2004). A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127: 294–299.
Vikis H, Sato M, James M, Wang D, Wang Y, Wang M et al. (2007). EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 67: 4665–4670.
Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI et al. (2009). A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15: 2552–2558.
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK et al. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070–2075.
Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS et al. (2007). Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 6: 661–667.
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L et al. (2005). Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561–5570.
Acknowledgements
Supported by grants from the National Institutes of Health RO1CA114465-04 (PAJ), R01CA135257-01 (PAJ, JAE, CL), R01CA137008-01 (JAE, PAJ), National Cancer Institute Lung SPORE P50CA090578 (PAJ, JAE and DJK), American Cancer Society RSG0610201CCE (PAJ, JAE), and the Hazel and Samuel Bellin research fund (PAJ).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Jänne receives royalties as a co-inventor on a patent awarded for the discovery of EGFR mutations, licensed to Genzyme Genetics, which was not involved in this study. Dr Christensen is an employee of Pfizer.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Ercan, D., Zejnullahu, K., Yonesaka, K. et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29, 2346–2356 (2010). https://doi.org/10.1038/onc.2009.526
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.526
Keywords
This article is cited by
-
Convergent evolution and multi-wave clonal invasion in H3 K27-altered diffuse midline gliomas treated with a PDGFR inhibitor
Acta Neuropathologica Communications (2022)
-
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis
Targeted Oncology (2020)
-
Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
Cancer Cell International (2019)
-
HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer
Molecular Genetics and Genomics (2019)
-
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
Oncogene (2016)